Trial Profile
A Phase I Study of Bevacizumab and Intravenous Ascorbic Acid for Patients With Recurrent High Grade Glioma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Ascorbic acid (Primary) ; Bevacizumab (Primary)
- Indications Glioma
- Focus Adverse reactions
- 25 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 02 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2016 New trial record